NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 126 filers reported holding NURIX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $18,210,601 | 1.88% |
| DAFNA Capital Management LLC | 556,695 | $5,561,383 | 1.52% |
| Deep Track Capital, LP | 2,997,830 | $29,948,322 | 1.39% |
| Redmile Group, LLC | 2,857,309 | $28,544,517 | 1.10% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,830,497 | 0.80% |
| Boxer Capital, LLC | 1,224,892 | $12,237 | 0.57% |
| AtonRa Partners | 30,142 | $301,119 | 0.47% |
| Affinity Asset Advisors, LLC | 100,000 | $999,000 | 0.35% |
| HARVARD MANAGEMENT CO INC | 314,762 | $3,144 | 0.31% |
| WASATCH ADVISORS LP | 3,869,775 | $38,659,052 | 0.23% |
| Delphia (USA) Inc. | 14,239 | $142,248 | 0.22% |
| Baker Brothers Advisors | 3,882,125 | $38,782,429 | 0.22% |
| GLOBEFLEX CAPITAL L P | 143,177 | $1,430,338 | 0.16% |
| ARK Investment Management | 2,261,071 | $22,588,099 | 0.15% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 280,760 | $2,804,792 | 0.15% |
| Corton Capital Inc. | 27,613 | $275,854 | 0.13% |
| Nebula Research & Development LLC | 16,025 | $160,090 | 0.12% |
| Candriam S.C.A. | 1,019,822 | $10,188,022 | 0.07% |
| Virtus ETF Advisers LLC | 9,912 | $99,021 | 0.06% |
| INNOVIS ASSET MANAGEMENT LLC | 15,648 | $156,324 | 0.06% |
External links
This page lists NURIX THERAPEUTICS INC's shareholders in Q2 2023. To view NURIX THERAPEUTICS INC's shareholder history, click here.